RxDoctor Payments Data

Donald Lawrence, MD

Medical Oncology · Boston, MANPI 1639181613

Payments from drug & device makers

$126,255in general payments, 2019–2025

Across 46 payments — averaging $2744.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Iovance Biotherapeutics, Inc.$84K
  • Merck$32K
  • AstraZeneca$9K
  • Partner Therapeutics, Inc.$1K

What the payments were for

  • Education$43100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Iovance Biotherapeutics, Inc.32$84,011
Merck11$32,371
AstraZeneca2$8,625
Partner Therapeutics, Inc.1$1,248

How this compares

$126,255 in reported general payments places this provider in the 55th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$104,029
Medicare patients
266
Services billed
1,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BraftoviEncorafenib13$204,254
MektoviBinimetinib13$200,310
Levothyroxine Sodium12$141
Morphine Sulfate ErMorphine Sulfate11$102
Prednisone16$78

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →